Cargando…

Time to treatment and mortality for clinical sepsis subtypes

BACKGROUND: Sepsis is common, deadly, and heterogenous. Prior analyses of patients with sepsis and septic shock in New York State showed a risk-adjusted association between more rapid antibiotic administration and bundled care completion, but not an intravenous fluid bolus, with reduced in-hospital...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Anne, Kennedy, Jason N., Reitz, Katherine M., Phillips, Gary, Terry, Kathleen M., Levy, Mitchell M., Angus, Derek C., Seymour, Christopher W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268363/
https://www.ncbi.nlm.nih.gov/pubmed/37322546
http://dx.doi.org/10.1186/s13054-023-04507-5
_version_ 1785059076880728064
author Yang, Anne
Kennedy, Jason N.
Reitz, Katherine M.
Phillips, Gary
Terry, Kathleen M.
Levy, Mitchell M.
Angus, Derek C.
Seymour, Christopher W.
author_facet Yang, Anne
Kennedy, Jason N.
Reitz, Katherine M.
Phillips, Gary
Terry, Kathleen M.
Levy, Mitchell M.
Angus, Derek C.
Seymour, Christopher W.
author_sort Yang, Anne
collection PubMed
description BACKGROUND: Sepsis is common, deadly, and heterogenous. Prior analyses of patients with sepsis and septic shock in New York State showed a risk-adjusted association between more rapid antibiotic administration and bundled care completion, but not an intravenous fluid bolus, with reduced in-hospital mortality. However, it is unknown if clinically identifiable sepsis subtypes modify these associations. METHODS: Secondary analysis of patients with sepsis and septic shock enrolled in the New York State Department of Health cohort from January 1, 2015 to December 31, 2016. Patients were classified as clinical sepsis subtypes (α, β, γ, δ-types) using the Sepsis ENdotyping in Emergency CAre (SENECA) approach. Exposure variables included time to 3-h sepsis bundle completion, antibiotic administration, and intravenous fluid bolus completion. Then logistic regression models evaluated the interaction between exposures, clinical sepsis subtypes, and in-hospital mortality. RESULTS: 55,169 hospitalizations from 155 hospitals were included (34% α, 30% β, 19% γ, 17% δ). The α-subtype had the lowest (N = 1,905, 10%) and δ-subtype had the highest (N = 3,776, 41%) in-hospital mortality. Each hour to completion of the 3-h bundle (aOR, 1.04 [95%CI, 1.02–1.05]) and antibiotic initiation (aOR, 1.03 [95%CI, 1.02–1.04]) was associated with increased risk-adjusted in-hospital mortality. The association differed across subtypes (p-interactions < 0.05). For example, the outcome association for the time to completion of the 3-h bundle was greater in the δ-subtype (aOR, 1.07 [95%CI, 1.05–1.10]) compared to α-subtype (aOR, 1.02 [95%CI, 0.99–1.04]). Time to intravenous fluid bolus completion was not associated with risk-adjusted in-hospital mortality (aOR, 0.99 [95%CI, 0.97–1.01]) and did not differ among subtypes (p-interaction = 0.41). CONCLUSION: Timely completion of a 3-h sepsis bundle and antibiotic initiation was associated with reduced risk-adjusted in-hospital mortality, an association modified by clinically identifiable sepsis subtype. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-023-04507-5.
format Online
Article
Text
id pubmed-10268363
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102683632023-06-15 Time to treatment and mortality for clinical sepsis subtypes Yang, Anne Kennedy, Jason N. Reitz, Katherine M. Phillips, Gary Terry, Kathleen M. Levy, Mitchell M. Angus, Derek C. Seymour, Christopher W. Crit Care Research BACKGROUND: Sepsis is common, deadly, and heterogenous. Prior analyses of patients with sepsis and septic shock in New York State showed a risk-adjusted association between more rapid antibiotic administration and bundled care completion, but not an intravenous fluid bolus, with reduced in-hospital mortality. However, it is unknown if clinically identifiable sepsis subtypes modify these associations. METHODS: Secondary analysis of patients with sepsis and septic shock enrolled in the New York State Department of Health cohort from January 1, 2015 to December 31, 2016. Patients were classified as clinical sepsis subtypes (α, β, γ, δ-types) using the Sepsis ENdotyping in Emergency CAre (SENECA) approach. Exposure variables included time to 3-h sepsis bundle completion, antibiotic administration, and intravenous fluid bolus completion. Then logistic regression models evaluated the interaction between exposures, clinical sepsis subtypes, and in-hospital mortality. RESULTS: 55,169 hospitalizations from 155 hospitals were included (34% α, 30% β, 19% γ, 17% δ). The α-subtype had the lowest (N = 1,905, 10%) and δ-subtype had the highest (N = 3,776, 41%) in-hospital mortality. Each hour to completion of the 3-h bundle (aOR, 1.04 [95%CI, 1.02–1.05]) and antibiotic initiation (aOR, 1.03 [95%CI, 1.02–1.04]) was associated with increased risk-adjusted in-hospital mortality. The association differed across subtypes (p-interactions < 0.05). For example, the outcome association for the time to completion of the 3-h bundle was greater in the δ-subtype (aOR, 1.07 [95%CI, 1.05–1.10]) compared to α-subtype (aOR, 1.02 [95%CI, 0.99–1.04]). Time to intravenous fluid bolus completion was not associated with risk-adjusted in-hospital mortality (aOR, 0.99 [95%CI, 0.97–1.01]) and did not differ among subtypes (p-interaction = 0.41). CONCLUSION: Timely completion of a 3-h sepsis bundle and antibiotic initiation was associated with reduced risk-adjusted in-hospital mortality, an association modified by clinically identifiable sepsis subtype. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-023-04507-5. BioMed Central 2023-06-15 /pmc/articles/PMC10268363/ /pubmed/37322546 http://dx.doi.org/10.1186/s13054-023-04507-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yang, Anne
Kennedy, Jason N.
Reitz, Katherine M.
Phillips, Gary
Terry, Kathleen M.
Levy, Mitchell M.
Angus, Derek C.
Seymour, Christopher W.
Time to treatment and mortality for clinical sepsis subtypes
title Time to treatment and mortality for clinical sepsis subtypes
title_full Time to treatment and mortality for clinical sepsis subtypes
title_fullStr Time to treatment and mortality for clinical sepsis subtypes
title_full_unstemmed Time to treatment and mortality for clinical sepsis subtypes
title_short Time to treatment and mortality for clinical sepsis subtypes
title_sort time to treatment and mortality for clinical sepsis subtypes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268363/
https://www.ncbi.nlm.nih.gov/pubmed/37322546
http://dx.doi.org/10.1186/s13054-023-04507-5
work_keys_str_mv AT yanganne timetotreatmentandmortalityforclinicalsepsissubtypes
AT kennedyjasonn timetotreatmentandmortalityforclinicalsepsissubtypes
AT reitzkatherinem timetotreatmentandmortalityforclinicalsepsissubtypes
AT phillipsgary timetotreatmentandmortalityforclinicalsepsissubtypes
AT terrykathleenm timetotreatmentandmortalityforclinicalsepsissubtypes
AT levymitchellm timetotreatmentandmortalityforclinicalsepsissubtypes
AT angusderekc timetotreatmentandmortalityforclinicalsepsissubtypes
AT seymourchristopherw timetotreatmentandmortalityforclinicalsepsissubtypes